Shire in €428m deal for Movetis
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Shire is set to buy the Belgian pharmaceutical group Movetis in a €428m (£354m) deal that will secure rights to Resolor, the €300m-a-year constipation treatment.
The €19-a-share deal is likely to go ahead after a number of Movetis's key backers, including the venture capital firm Sofinnova, backed the takeover. The offer is at a 74 per cent premium to Movetis's price on Monday.
The takeover of the gastrointestinal treatment specialist fits with Shire's business plan of bolting on groups with exposure to the specialist drug market.
"This proposed acquisition of Movetis provides a highly complementary fit for our [gastrointestinal] business unit and supports our strategy of expanding our specialty product portfolio into international markets," said Mike Cola, the president of Shire's specialty pharmaceutical business.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments